Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.

Mingfeng LiuTeng GuoZhixue MaLiying DuJuan HouYuan TianMeng MengXinran Chen

Published in: Therapeutic drug monitoring (2024)

NDI C min was an independent risk factor for serious adverse reactions, with a threshold of 665 ng/mL. Monitoring NDI C min was beneficial for the rational application of imatinib and individualized treatment of patients with gastrointestinal stromal tumors.

Keyphrases

chronic myeloid leukemia
adverse drug
emergency department
replacement therapy